Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceuticals company, acquires Ikaria, Inc. for total consideration of approximately $2.3 billion thereby adding to its portfolio INOMAX® (inhaled nitric oxide), a vital treatment option for a highly vulnerable patient population. In the context of this acquisition Mallinckrodt plc entered into debt financing commitments with affiliates of Barclays Capital, Deutsche Bank and Goldman Sachs. VISCHER advises Mallinckrodt on the Swiss law aspects of the financing. The VISCHER- team is lead by Dr. Matthias Staehelin and Dr. Adrian Dörig (both Partner), both Corporate, Christoph Niederer (Partner) Tax and includes Janusz Marty (Senior Associate) and Manuel Ulrich (Associate) both Corporate.